Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 20:13:1295030.
doi: 10.3389/fonc.2023.1295030. eCollection 2023.

Review: therapeutic approaches for circadian modulation of the glioma microenvironment

Affiliations
Review

Review: therapeutic approaches for circadian modulation of the glioma microenvironment

Ella A Nettnin et al. Front Oncol. .

Abstract

High-grade gliomas are malignant brain tumors that are characteristically hard to treat because of their nature; they grow quickly and invasively through the brain tissue and develop chemoradiation resistance in adults. There is also a distinct lack of targeted treatment options in the pediatric population for this tumor type to date. Several approaches to overcome therapeutic resistance have been explored, including targeted therapy to growth pathways (ie. EGFR and VEGF inhibitors), epigenetic modulators, and immunotherapies such as Chimeric Antigen Receptor T-cell and vaccine therapies. One new promising approach relies on the timing of chemotherapy administration based on intrinsic circadian rhythms. Recent work in glioblastoma has demonstrated temporal variations in chemosensitivity and, thus, improved survival based on treatment time of day. This may be due to intrinsic rhythms of the glioma cells, permeability of the blood brain barrier to chemotherapy agents, the tumor immune microenvironment, or another unknown mechanism. We review the literature to discuss chronotherapeutic approaches to high-grade glioma treatment, circadian regulation of the immune system and tumor microenvironment in gliomas. We further discuss how these two areas may be combined to temporally regulate and/or improve the effectiveness of immunotherapies.

Keywords: chronotherapy; circadian; glioblastoma; glioma; pediatric high-grade glioma; tumor microenvironment (TME).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schema displaying circadian regulation of high-grade glioma extracellular microenvironment at two different points in the circadian cycle. High-grade glioma microenvironment represented at two different points in the circadian cycle. When BMAL1 and CLOCK levels are high and PER and CRY levels are low (Left), there is an increase in pro-angiogenic factors, mesenchymal differentiation, inflammatory cytokine release, and immunosuppressive microglia. When BMAL1 and CLOCK levels are low and PER and CRY levels are high (Right), there is reduced angiogenesis, suppression of EMT, reduced inflammatory markers, and reduced recruitment of immunosuppressive microglia and expression of PD-L1. Created with BioRender.com.
Figure 2
Figure 2
Schema illustrating circadian regulation of angiogenesis, inflammation, EMT, and immune suppression. The CLOCK-BMAL1 complex regulates expression of proangiogenic factors and microvascular density (A). CLOCK upregulates NF-kB activity, thus inducing expression of mesenchymal proteins and transcription factors (B). The CLOCK-BMAL1-IL-1B-LDHA axis regulates expression of lactate and proinflammatory cytokines (C). The CLOCK-BMAL1 complex regulates recruitment of immunosuppressive microglia and expression of immune inhibitory checkpoints (D). Created with BioRender.com.

Similar articles

Cited by

References

    1. Damato AR, Herzog ED. Circadian clock synchrony and chronotherapy opportunities in cancer treatment. Semin Cell Dev Biol (2022) 126:27–36. doi: 10.1016/j.semcdb.2021.07.017 - DOI - PMC - PubMed
    1. Schibler U, Sassone-Corsi P. A web of circadian pacemakers. Cell (2002) 111(7):919–22. doi: 10.1016/S0092-8674(02)01225-4 - DOI - PubMed
    1. Arafa K, Emara M. Insights about circadian clock and molecular pathogenesis in gliomas. Front Oncol (2020) 10:199. doi: 10.3389/fonc.2020.00199 - DOI - PMC - PubMed
    1. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, et al. . Role of the CLOCK protein in the mammalian circadian mechanism. Science (1998) 280(5369):1564–9. doi: 10.1126/science.280.5369.1564 - DOI - PubMed
    1. Preitner N, Damiola F, Luis Lopez M, Zakany J, Duboule D, Albrecht U, et al. . The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell (2002) 110( 2):251–60. doi: 10.1016/s0092-8674(02)00825-5 - DOI - PubMed